ArticleJournal of biochemical and molecular toxicology2026
Protective Potential of Vinpocetine on Acrylamide Induced Liver Toxicity in Male Albino Rats.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acrylamide is a highly reactive carbonyl compound extensively utilized in industrial applications. It shows a significant association with oxidative stress, neurotoxic, and genotoxic effects. This study sought to assess the protective effects of vinpocetine, a synthetic analog of the natural alkaloid vincamine, which exhibits strong antioxidant and anti-inflammatory properties, against ACR-induced hepatic injury. Experimental animals were categorized into four groups and orally treated as follows: control group, Vinpo. group (5 mg/kg bw), Acrylamide group (38.27 mg/kg bw), and Vinpo. plus acrylamide group. Following the experimental period, biochemical analyses revealed that ACR administration significantly elevated hepatic marker enzymes and lipid profile as well as increased oxidative stress markers such as malondialdehyde (MDA) and tumor necrosis factor (TNF-α) immunoexpression levels, with concomitant reductions in antioxidant defenses (catalase "CAT" and superoxide dismutase "SOD"). Conversely, co-administration of vinpocetine mitigated the ACR-induced alterations and helped in the normalization of biochemical parameters, enhancing antioxidant capacity and attenuation of histopathological damage and apoptotic processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.